In the subgroup without diabetes (n = 3), the pooled analysis did not reach statistical significance (HR = 0.45, 95% CI: 0.03–5.92, p = 0.31), Figure 8B. The effect direction remained favorable, suggesting a potential benefit of SGLT2 inhibitors in this population, albeit with high uncertainty. This evidence concerns the gene SLC5A2 and diabetes mellitus.